Incyte Corp (INCY) Q2 2020 Earnings Call Transcript
INCY earnings call for the period ending June 30, 2020.
Incyte
INCY
INCY
$94.32
-$1.24
-1.3%
Price as of August 14, 2020, 3:40 p.m. EDT
View Interactive INCY Charts
The Company is a drug discovery and development company focused on developing proprietary small molecule drugs to treat serious unmet medical needs.
Interactive Chart
News & Analysis: Incyte
The Fool has written over 200 articles on Incyte.
Here's Why Incyte Rose 19.1% in the First Half of 2020
Incyte might finally be convincing Wall Street that its pipeline is the real deal.
Incyte Corp (INCY) Q1 2020 Earnings Call Transcript
INCY earnings call for the period ending March 31, 2020.
Why Incyte's Q1 Loss Isn't As Bad As It Looks
The biotech's revenue increased solidly in Q1. And it had a very good explanation for its net loss.
Incyte Reports a Q1 Loss Due to MorphoSys Deal
The biotech's revenue soared thanks to the continued success of Jakafi, but its bottom line was weighed down by a licensing deal.
Is Incyte Stock a Buy?
Is the biotech company worth its rich valuation metrics?
Incyte to Test Its Cancer Drug Jakafi as a Treatment for COVID-19
Both diseases involve an overactive immune system.
These 2 Things Will Help Incyte’s Stock Rebound
Here's why Incyte could recover from its poor performance in recent weeks.
Incyte's Ruxolitinib Works in Patients With Eczema
The biotech company just reported data from a pair of successful late-stage clinical trials.
Better Buy: Vertex Pharmaceuticals vs. Incyte
Big drug developers reinvest revenues from cash-cow products to fuel the pipeline for the future.
